Scientific deep-dive
GLP-1 Drugs After 65: Strength, Not Just Weight
Grip strength held up in general adult trials even as lean mass fell. In older adults with type 2 diabetes, prolonged use has been linked to the opposite, and a 2024 review found no concise guidelines for this age group.
The reassuring finding about muscle comes from trials in general adult populations, and it is real. Handgrip strength has held up in short and medium-term trials of semaglutide and liraglutide even while lean soft tissue fell.[1] The trouble is that the picture changes in the group most likely to be harmed by muscle loss. Longitudinal and retrospective research in older adults with type 2 diabetes reports the opposite: reduced grip strength and accelerated sarcopenia with prolonged semaglutide use.[1] A 2024 review found no concise guidelines for prescribing these drugs after 65.[3] The studies that do include older adults, none of them designed around them, are gathered in our after-65 reading list.
Mass and strength are not the same measurement
Most of the argument about muscle on these drugs is about mass, because mass is what a DXA scanner measures and what body-composition substudies report. Our lean mass article works through that evidence, and the short version is more reassuring than the headlines: lean tissue accounts for roughly a quarter to a third of weight lost, and intensive lifestyle programs cost a comparable share.
Strength is a different variable. It is what decides whether someone can rise from a chair without using their arms, carry shopping, or recover a stumble instead of falling. Grip strength is the standard proxy, and it is one of the defining components of sarcopenia in its own right.
Strength decides whether someone can rise from a chair without using their arms.
What the strength evidence shows, by age
| Population | What was observed |
|---|---|
| Adults with obesity, short to mid-term trials | Grip strength statistically preserved despite reductions in lean soft-tissue mass — strength did not fall in proportion to weight[1] |
| Older adults with type 2 diabetes, prolonged use | Reduced grip strength and accelerated sarcopenia in longitudinal and retrospective research[1] |
Two things separate the last row from the first. One is age, and the fact that muscle mass and strength are already declining before any drug is involved. The other is duration: the reassuring results come from short and medium-term trials, and the concerning ones from prolonged use. A treatment intended to continue indefinitely is not well described by a 68-week trial.
Who carries the most risk
A 2025 review looked at the groups already predisposed to sarcopenia before a GLP-1 enters the picture, and made the obvious but under-stated point: the same proportional loss lands harder on someone with less reserve.[2] It puts lean mass at as much as 15 to 40% of total weight lost, and notes that evidence on body composition is insufficient in older adults, and equally so in chronic kidney disease, liver disease and inflammatory bowel disease.
- Anyone already frail, or recently hospitalized. Reserve is the variable, not percentage lost.
- Anyone with sarcopenic obesity (high fat and low muscle together). It is common after 65 and easy to miss because the scale looks like a straightforward obesity problem.[3]
- Anyone eating substantially less than they were. The appetite suppression that drives the weight loss can also undercut protein intake, at the age when protein matters most.
- Anyone not doing resistance work. The reviews agree on this even where they agree on little else.
What is actually recommended, and by whom
A 2024 review of obesity pharmacotherapy in adults 65 and over found the general-population efficacy and safety data increasingly favorable, but concise guidelines for older adults unavailable.[3] It calls for trials that measure geriatric outcomes rather than weight alone.
So a prescriber weighing this for someone in their seventies is extrapolating from trials whose average participant was decades younger, without a guideline to work from. An effective drug can still be the right call for an older patient, but the usual scaffolding is missing, so it is worth asking what is being monitored instead.
The reviews do converge on two unglamorous things: adequate protein, and resistance training, from the start rather than after a loss.[2] Our protein calculator works a target from body weight, and the exercise pairing tool sets out the training side. For the same question framed around the menopausal transition rather than age 65, see GLP-1 drugs after menopause.
Frequently Asked Questions
References
- 1.Prokopidis K. Glucagon-like peptide-1 receptor agonists and muscle strength changes in older adults: Risks beyond muscle mass reductions British Journal of Pharmacology. 2026. PMID: 41577337.
- 2.Memel Z, Gold SL, Pearlman M, et al. Impact of GLP-1 Receptor Agonist Therapy in Patients High Risk for Sarcopenia Current Nutrition Reports. 2025. PMID: 40289060.
- 3.Žižka O, Haluzík M, Jude EB. Pharmacological Treatment of Obesity in Older Adults Drugs & Aging. 2024. PMID: 39514148.
Compare the sellers
Related research
Ozempic and the Vagina: Dryness, Odor and Yeast Infections
No GLP-1 label lists a vaginal side effect. Genital yeast infections belong to SGLT2 diabetes drugs such as Jardiance, and GLP-1 users had fewer of them in cohort studies. What FDA reports show, likely causes of dryness and odor, and when to see a clinician.
11 min read
Exenatide (Byetta, Bydureon): The First GLP-1, Its Weight Loss and Where It Went
Exenatide, sold as Byetta and Bydureon BCise, was the first GLP-1 drug. It is approved only for type 2 diabetes, produces far less weight loss than semaglutide, and both brands are discontinued in the US. Its one generic is now listed as discontinued too.
10 min read
Eating Too Little on a GLP-1: What the Deficiency Data Show
Across 480,825 adults, more than 60% took in less calcium and iron than their estimated requirements, vitamin D deficiency reached 13.6% at a year, and ferritin ran 26–30% below an active comparator.
7 min read
Holding a GLP-1 Before Endoscopy or Surgery: What the Trial Found
A 2026 randomized trial put retained stomach contents at 3.1% when one dose was held against 25.0% when it was not, and found something more useful about the day-before diet.
7 min read
GLP-1 Drugs and Suicidal Thoughts: The Warning Came Off in 2026
In February 2026 the Suicidal Behavior and Ideation section was removed from the Wegovy, Zepbound and Saxenda labels, after three large studies looked for a signal and none found one.
7 min read
Phentermine and a GLP-1 Together: What the Labels and Trials Show
Phentermine's label says combining it with any other weight-loss drug is not recommended; the Wegovy and Zepbound labels never mention it. The one trial, with liraglutide, found no meaningful extra loss. No semaglutide or tirzepatide trial exists.
10 min read
Where to get tirzepatide online, safely: sellers our editors have checked
These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.
No insurance needed · vetted by our editors
Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more
Embody
From $129/mo
Get started →Luvo Health
Moving between compounded and brand without changing seller
From $179/mo
Get started →Eden
Coverage in all 50 states, which most sellers will not confirm
From $129/mo
Get started →